» Articles » PMID: 32124588

Meeting the Challenge of Diabetes in China

Overview
Date 2020 Mar 4
PMID 32124588
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

China's estimated 114 million people with diabetes pose a massive challenge for China's health policy-makers who have significantly extended health insurance coverage over the past decade. What China is doing now, what it has achieved, and what remains to be done should be of interest to health policy-makers, worldwide. We identify the challenges posed by China's two principal strategies to tackle diabetes: (1) A short-term pilot strategy of health promotion, detection and control of chronic diseases in 265 national demonstration areas (NDAs); and (2) A long-term strategy to extend health promotion and strengthen primary care capacity and health system integration throughout China. Finally, we consider how Chinese innovations in artificial intelligence (AI) and Big Data may contribute to improving diagnosis, controlling complications and increasing access to care. Health system integration in China will require overcoming the fragmentation of a system that still places excessive reliance on local government financing. Moreover, what remains to be done resembles deeper challenges faced by healthcare systems worldwide: the need to upgrade primary care and reduce inequalities in access to health services.

Citing Articles

Changes in pre-diabetes and diabetes prevalence and diabetes self-management behaviors across socioeconomic spectra in rural southwest China: 2013-2022.

Wu X, Li G, Liu L, Li H, Zhao Y, Golden A BMC Public Health. 2025; 25(1):594.

PMID: 39948504 PMC: 11823096. DOI: 10.1186/s12889-025-21763-y.


AI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges.

He Z, Li W Diabetes Metab Syndr Obes. 2025; 18():85-92.

PMID: 39802619 PMC: 11718508. DOI: 10.2147/DMSO.S495364.


Research hotspots and trends in diabetes and insulin resistance: a bibliometric analysis.

Zhang S, Yan H, Cao D, Sun W, Li J, Xu J Front Nutr. 2024; 11:1480491.

PMID: 39737158 PMC: 11684393. DOI: 10.3389/fnut.2024.1480491.


Treatment Patterns and Glycaemic Control Between 2015 and 2019 in Tianjin, China: A Real-World Study of Adults with Type 2 Diabetes.

Zhang Q, Fan Y, Liu X, Zhang M, Zhang J, Du Q Diabetes Ther. 2024; 16(1):1-14.

PMID: 39487283 PMC: 11759750. DOI: 10.1007/s13300-024-01661-z.


Poricoic acid a ameliorates high glucose-induced podocyte injury by regulating the AMPKα/FUNDC1 pathway.

Wu Y, Xu Y, Deng H, Sun J, Li X, Tang J Mol Biol Rep. 2024; 51(1):1003.

PMID: 39305364 DOI: 10.1007/s11033-024-09921-8.


References
1.
Fagherazzi G, Ravaud P . Digital diabetes: Perspectives for diabetes prevention, management and research. Diabetes Metab. 2018; 45(4):322-329. DOI: 10.1016/j.diabet.2018.08.012. View

2.
Hu C, Jia W . Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication. Diabetes. 2017; 67(1):3-11. DOI: 10.2337/dbi17-0013. View

3.
Bragg F, Holmes M, Iona A, Guo Y, Du H, Chen Y . Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China. JAMA. 2017; 317(3):280-289. PMC: 6520233. DOI: 10.1001/jama.2016.19720. View

4.
Li J, Li J, Zhang J, Jin R, Ma S, Deng G . [Study on the overall implementation status of the National Demonstration Areas for Comprehensive Prevention and Control of Non-communicable Diseases]. Zhonghua Liu Xing Bing Xue Za Zhi. 2018; 39(4):417-421. DOI: 10.3760/cma.j.issn.0254-6450.2018.04.006. View

5.
Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q . Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017; 317(24):2515-2523. PMC: 5815077. DOI: 10.1001/jama.2017.7596. View